Overview

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.

Phase:

Phase 4

Details

Lead Sponsor:

Kowa Research Institute, Inc.

Treatments:

Pitavastatin
Pravastatin